XML 14 R3.htm IDEA: XBRL DOCUMENT v3.20.4
Unaudited Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Revenues $ 23,632 $ 17,915 $ 65,961 $ 45,697
Cost of revenues 19,676 16,329 51,444 38,770
Gross margin 3,956 1,586 14,517 6,927
Operating expenses:        
Research and development 3,029 2,049 8,248 6,920
Selling, general and administrative 7,085 6,071 18,609 16,726
Amortization of acquisition-related intangibles 360 85 601 255
Change in fair value of contingent consideration 2,740 2,740
Total operating expenses 13,214 8,205 30,198 23,901
Operating loss (9,258) (6,619) (15,681) (16,974)
Change in fair value of warrants 556 4,648
Interest income, net 53 262 373 1,101
Other (expense)/income, net (274) (932) (920) 45
Loss before income tax expense (benefit) (9,479) (6,733) (16,228) (11,180)
Income tax expense (benefit) (1,546) 112 (1,166) 29
Net loss $ (7,933) $ (6,845) $ (15,062) $ (11,209)
Net loss per common share        
Basic (in dollars per share) $ (0.31) $ (0.32) $ (0.65) $ (0.54)
Diluted (in dollars per share) $ (0.31) $ (0.35) $ (0.65) $ (0.75)
Weighted average number of common shares outstanding        
Basic (in shares) 25,470 21,185 23,011 20,786
Diluted (in shares) 25,470 21,203 23,011 20,894